BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tesdal IK, Wikström M, Flechtenmacher C, Filser T, Dueber C. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol. 2006;29:778-784. [PMID: 16779690 DOI: 10.1007/s00270-005-0063-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Zhang H, Zhao H, Wang X, Tsauo J, Luo X, Li X. Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Diagn Interv Radiol. 2014;20:487-491. [PMID: 25297389 DOI: 10.5152/dir.2014.13493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
2 Wang N, Guan Q, Wang K, Zhu B, Yuan W, Zhao P, Wang X, Zhao Y. TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol. 2011;28:1038-1043. [PMID: 20632218 DOI: 10.1007/s12032-010-9620-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
3 Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Dai S, Yao JN, Liu FQ. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World J Gastroenterol 2015; 21(43): 12439-12447 [PMID: 26604651 DOI: 10.3748/wjg.v21.i43.12439] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
4 Donahue LA, Kulik L, Baker T, Ganger DR, Gupta R, Memon K, Abecassis MM, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2013;24:74-80. [PMID: 23273699 DOI: 10.1016/j.jvir.2012.09.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
5 Horikawa M, Miyayama S, Irie T, Kaji T, Arai Y. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. American Journal of Roentgenology 2015;205:764-73. [DOI: 10.2214/ajr.15.14825] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
6 Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK, Fidelman N. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36:1336-1343. [PMID: 23864021 DOI: 10.1007/s00270-013-0698-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
7 Gu L, Liu H, Fan L, Lv Y, Cui Z, Luo Y, Liu Y, Li G, Li C, Ma J. Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2014;140:199-210. [PMID: 24077865 DOI: 10.1007/s00432-013-1528-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
8 Park BV, Gaba RC, Lokken RP. Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt. Semin Intervent Radiol. 2016;33:337-341. [PMID: 27904254 DOI: 10.1055/s-0036-1592319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Lake-Bakaar G, Ahmed M, Evenson A, Bonder A, Faintuch S, Sundaram V. Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law. Liver Cancer 2014;3:428-38. [PMID: 26280004 DOI: 10.1159/000343871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Kang JW, Kim JH, Ko GY, Gwon DI, Yoon HK, Sung KB. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 2012;53:545-50. [PMID: 22547388 DOI: 10.1258/ar.2012.110476] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
11 Knüppel E, Bettinger D, Euringer W, Thimme R, Roessle M, Spangenberg HC, Schultheiβ M. Influence of the transjugular intrahepatic portosystemic stent on firstline treatment of hepatocellular carcinoma. Hepatology 2013;58:2211-2. [PMID: 23519917 DOI: 10.1002/hep.26406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
12 Sellers CM, Nezami N, Schilsky ML, Kim HS. Transjugular intrahepatic portosystemic shunt as a bridge to liver transplant: Current state and future directions. Transplant Rev (Orlando) 2019;33:64-71. [PMID: 30477811 DOI: 10.1016/j.trre.2018.10.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Gordon AC, Gupta AN, Gabr A, Thornburg BG, Kulik LM, Ganger DR, Maddur H, Flamm SL, Boike JR, Moore CM, Borja-Cacho D, Christopher DA, Katariya NN, Ladner DP, Caicedo-Ramirez JC, Riaz A, Salem R, Lewandowski RJ. Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol 2021;32:211-9. [PMID: 33349507 DOI: 10.1016/j.jvir.2020.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wang S, Zhuang L, Meng Z. Hepatocellular Carcinoma More Than 3 cm in Diameter: A Systematic Review of Transcatheter Arterial Chemoembolization Plus Percutaneous Ethanol Injection versus Transcatheter Arterial Chemoembolization Alone. ISRN Gastroenterol 2013;2013:526024. [PMID: 23936659 DOI: 10.1155/2013/526024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
15 Kohi MP, Fidelman N, Naeger DM, LaBerge JM, Gordon RL, Kerlan RK. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol. 2013;24:68-73. [PMID: 23176968 DOI: 10.1016/j.jvir.2012.08.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
16 Padia SA, Chewning RH, Kogut MJ, Ingraham CR, Johnson GE, Bhattacharya R, Kwan SW, Monsky WL, Vaidya S, Hippe DS. Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts. Cardiovasc Intervent Radiol. 2015;38:913-921. [PMID: 25373795 DOI: 10.1007/s00270-014-1009-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
17 Fan W, Guo J, Zhu B, Wang S, Yu L, Huang W, Fan H, Li F, Wu Y, Zhao Y, Wang Y, Xue M, Wang H, Li J. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. Eur Radiol 2021. [PMID: 33893536 DOI: 10.1007/s00330-021-07834-9] [Reference Citation Analysis]
18 Miura JT, Rilling WS, White SB, Hieb RA, Tutton SM, Patel PJ, Gamblin TC, Hohenwalter EJ. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB (Oxford). 2015;17:707-712. [PMID: 26172137 DOI: 10.1111/hpb.12433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
19 Guan YS, He Q. A current update on the rule of alternative and complementary medicine in the treatment of liver diseases. Evid Based Complement Alternat Med 2013;2013:321234. [PMID: 24109491 DOI: 10.1155/2013/321234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
20 Chen X, Qiu ZK, Wang GB, Chen XL, Zhang FJ, Gao F. Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Diagn Interv Radiol 2021;27:671-6. [PMID: 34318755 DOI: 10.5152/dir.2021.20358] [Reference Citation Analysis]
21 Tao R, Li X, Ran R, Xiao Z, Zhang H, Kong H, Song Q, Huang Y, Wang L, Huang J. A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. Oncotarget 2017;8:5460-73. [PMID: 27705924 DOI: 10.18632/oncotarget.12348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Zou LQ, Zhang BL, Chang Q, Zhu FP, Li YY, Wei YQ, Guan YS. 3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20(45): 17227-17234 [PMID: 25493039 DOI: 10.3748/wjg.v20.i45.17227] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]